(MedPage Today) — The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.
The subcutaneous anti-interleukin…
Source link : https://www.medpagetoday.com/allergyimmunology/asthma/119054
Author :
Publish date : 2025-12-17 13:56:00
Copyright for syndicated content belongs to the linked Source.
